Form 4: LifeMD Director MacRae Receives 22,365 Restricted Shares

LifeMD, Inc. Director Calum Archibald MacRae was granted 22,365 restricted shares of common stock, vesting on June 1, 2026.

Summary

• Calum Archibald MacRae, a Director of LifeMD, Inc. (LFMD), acquired 22,365 shares of common stock.
• The transaction occurred on October 2, 2025, and was a grant of restricted shares.
• The acquisition price per share was $0.
• Following this transaction, Calum Archibald MacRae directly beneficially owns 38,865 shares of common stock.
• The granted restricted shares are scheduled to vest on June 1, 2026.

Sentiment

Score: 6

Explanation: The grant of restricted shares to a director is a standard compensation practice that aligns management's interests with shareholders, indicating confidence in future performance. It is a neutral to slightly positive event.

Positives

• The grant of restricted shares to a director aligns management's interests with those of shareholders, potentially motivating long-term performance.
• This is a standard form of executive compensation, indicating ongoing commitment from the director.

Negatives

• The shares are restricted and do not provide immediate liquidity or cash value to the director until they vest.
• The transaction price was $0, meaning no direct capital inflow to the company from this specific share acquisition.

Future Outlook

The restricted shares granted to Director MacRae are set to vest on June 1, 2026, indicating a future milestone for this compensation package.

Industry Context

The grant of restricted stock to a director is a common practice in publicly traded companies across various industries, used to incentivize long-term performance and align executive interests with shareholder value.

Related Party Transactions

• Grant of restricted shares to a director, which is considered an insider transaction.

Stakeholder Impact

• Shareholders: Potential benefit from increased alignment of the director's interests with company performance and long-term value creation.

Next Steps

• The restricted shares will vest on June 1, 2026, at which point they will become fully owned by the director.

Key Dates

Keywords

LifeMD, LFMD, Calum Archibald MacRae, Director, Restricted Stock, Insider Transaction, SEC Form 4, Beneficial Ownership, Equity Grant